Hikma Pharmaceuticals (LON:HIK) Sets New 1-Year High - Here's Why

Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) hit a new 52-week high on Thursday . The company traded as high as GBX 2,296 ($28.48) and last traded at GBX 2,294 ($28.45), with a volume of 311692 shares trading hands. The stock had previously closed at GBX 2,282 ($28.31).

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank upped their target price on Hikma Pharmaceuticals from GBX 2,400 ($29.77) to GBX 2,560 ($31.75) and gave the company a "buy" rating in a research report on Wednesday, January 29th.

Hikma Pharmaceuticals Stock Down 0.4 %

The stock has a 50 day moving average of GBX 2,051.65 and a 200 day moving average of GBX 1,968.34. The firm has a market capitalization of £5.07 billion, a price-to-earnings ratio of 3,513.85, a P/E/G ratio of 2.38 and a beta of 0.41. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.48.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.